EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Drug–Drug Interactions of Cenobamate With Medications: Dose‐Dependent Induction/Inhibition and Clinical Implications

Hiroyuki Ichida iD, Takaharu Nakao iD, Takanori Mori, Reina Makino, Marika Nakagawa, Kazuhiro Yoneda iD, Yoshiyuki Yamaura iD, Masanori Kuribayashi

CPT: Pharmacometrics & Systems Pharmacology · 2026-11 · 15 (11)

DOI: 10.1002/psp4.70358 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, online erschienen am 04.11.2026. Verfasst von Hiroyuki Ichida und 7 weiteren Autor:innen. Beteiligte Einrichtung: Safety & Pharmacokinetic Research, Ono Pharmaceutical Co., Ltd., Osaka, Japan. Hauptthemen laut MEDLINE: Tetrazoles, Carbamates. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ono Pharmaceutical Co. Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cenobamate causes dose‐dependent cytochrome P450 (CYP)2B6 and CYP3A4 induction and CYP2C19 inhibition, raising concern over multi‐pathway drug–drug interactions (DDIs) in patients with epilepsy treated with cardiovascular co‐medications. We developed a physiologically based pharmacokinetic (PBPK) model for cenobamate and verified it using reported DDIs for cenobamate 200 mg using three probe substrates: bupropion (CYP2B6), midazolam (CYP3A4), and omeprazole (CYP2C19). The verified model predicted exposure changes (area under the curve ratio [AUCR] and maximum concentration [Cmax] ratio with/without cenobamate) for eight drugs, including anticoagulants and antiplatelets (apixaban, cilostazol, clopidogrel, and rivaroxaban), and antihypertensives (amlodipine, bisoprolol, carvedilol, and nifedipine). Regarding anticoagulants and antiplatelets, for apixaban, AUCR/Cmax ratios were 0.78/0.92 (100 mg), 0.71/0.87 (200 mg), and 0.63/0.83 (400 mg), respectively. For cilostazol, parent exposure decreased (0.67/0.85, 0.55/0.77, 0.45/0.70), while the active metabolite OPC‐13015 was predicted to increase in Cmax. For clopidogrel, parent exposure was unchanged, but formation of 2‐oxo‐clopidogrel and clopidogrel‐H4 were decreased and increased, respectively. For rivaroxaban, the AUCR/Cmax ratios were 0.78/0.90, 0.69/0.85, and 0.61/0.80. Among antihypertensives, amlodipine showed decreased AUCR/Cmax ratios (0.57/0.66, 0.45/0.55, 0.37/0.47). The exposure changes of bisoprolol were minor (AUCR 0.84–0.92, Cmax ratio 0.95–0.98); AUCR/Cmax ratios of carvedilol fell to 0.73/0.80, 0.63/0.71, and 0.55/0.64; and nifedipine decreased markedly (0.41/0.54, 0.29/0.41, 0.21/0.32). In conclusion, cenobamate induced CYP2B6 weakly and CYP3A4 moderately, and it inhibited CYP2C19 moderately to drive dose‐dependent decreases in exposure for seven of eight drugs with minimal change for bisoprolol. The verified PBPK framework enables risk assessment in scenarios not yet clinically tested.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TetrazolesCarbamatesHumansDrug InteractionsDose-Response Relationship, DrugCytochrome P-450 CYP3AModels, BiologicalCytochrome P-450 CYP2B6Cytochrome P-450 CYP2C19Antihypertensive AgentsArea Under CurveAnticoagulantsCytochrome P-450 CYP2C19 InhibitorsChlorophenols

Stichwörter der Autor:innen

CYP2B6CYP2C19CYP3A4cenobamatedrug–drug interactionphysiologically based pharmacokinetics

Substanzen

CenobamateTetrazolesCytochrome P-450 CYP3ACarbamatesCYP3A4 protein, humanCytochrome P-450 CYP2B6Cytochrome P-450 CYP2C19CYP2B6 protein, humanCYP2C19 protein, humanAntihypertensive Agents

Autor:innen und Institutionen

  • Safety & Pharmacokinetic Research, Ono Pharmaceutical Co., Ltd., Osaka, Japan.
  • Medical Affairs, Ono Pharmaceutical Co., Ltd., Osaka, Japan.

ORCID-Profile: Hiroyuki Ichida, Takaharu Nakao, Kazuhiro Yoneda, Yoshiyuki Yamaura

Förderung

  • Ono Pharmaceutical Co. Ltd

Zitieren

APA

Ichida, H., Nakao, T., Mori, T., Makino, R., Nakagawa, M., Yoneda, K., Yamaura, Y., & Kuribayashi, M. (2026). Drug–Drug Interactions of Cenobamate With Medications: Dose‐Dependent Induction/Inhibition and Clinical Implications. CPT: Pharmacometrics & Systems Pharmacology, 15(11). https://doi.org/10.1002/psp4.70358

Vancouver

Ichida H, Nakao T, Mori T, Makino R, Nakagawa M, Yoneda K, et al. Drug–Drug Interactions of Cenobamate With Medications: Dose‐Dependent Induction/Inhibition and Clinical Implications. CPT: Pharmacometrics & Systems Pharmacology. 2026;15(11). doi:10.1002/psp4.70358

BibTeX
@article{Ichida2026,
  author = {Ichida, Hiroyuki and Nakao, Takaharu and Mori, Takanori and Makino, Reina and Nakagawa, Marika and Yoneda, Kazuhiro and Yamaura, Yoshiyuki and Kuribayashi, Masanori},
  title = {Drug–Drug Interactions of Cenobamate With Medications: Dose‐Dependent Induction/Inhibition and Clinical Implications},
  journal = {CPT: Pharmacometrics & Systems Pharmacology},
  year = {2026},
  volume = {15},
  number = {11},
  doi = {10.1002/psp4.70358}
}
Kostenlos starten →